Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain.

Pharmacogenomics - 1 Jan 2026

Kronenbuerger Martin, Magarbeh Leen, Kloiber Stefan, Tavakoli Emytis, Gorbovskaya Ilona, Tiwari Arun, Kennedy James L, Karp Jordan F, Muller Daniel J, Elsheikh Samar S M

Abstract excerpt

BACKGROUND: Late-life depression (LLD) and chronic low back pain frequently co-occur and exacerbate one another. Outcomes with antidepressant treatment in this population are often suboptimal. Pharmacogenetic factors may help explain variability in antidepressant response. Building on prior findings suggesting that SLC6A2 variation predicts venlafaxine response in LLD, we examined whether such genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Pain
Share to Depression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Low Back Pain

Share to Norepinephrine Plasma Membrane Transport Proteins

Share to Pharmacogenetics

Share to Receptor, Serotonin, 5-HT1A

Share to Serotonin Plasma Membrane Transport Proteins

Share to Venlafaxine Hydrochloride

Source

Open in PubMed Open full text

Identifiers

PMID: 42101172
DOI: 10.1080/14622416.2026.2669395
PMCID: PMC13203058

Genes

SLC6A2
HTR1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain.PMID 42101172Read ↗

Comorbid chronic pain and depression: Shared risk factors and differential antidepressant effectivenessSemantic proximity Read ↗

Symptoms of depression in chronic pain: prevalence in UK Biobank and shared genetic factorsSemantic proximity Read ↗

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Semantic proximity Read ↗

5HTTLPR Genetic Variant and Major Depressive Disorder: A Review.Semantic proximity Read ↗

Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studiesSemantic proximity Read ↗

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Semantic proximity Read ↗

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.Semantic proximity Read ↗

The Pharmacogenetics of Depression: Enter the GWASSemantic proximity Read ↗

Addendum: Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways.Semantic proximity Read ↗

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Semantic proximity Read ↗

Understanding antidepressant change patterns in the UK BiobankSemantic proximity Read ↗

Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.